Products

Erbitux Injection (Cetuximab): Targeted EGFR Inhibitor Therapy – Global Supply by Ernest Oncology In the advanced oncological landscape of 2026, Erbitux (Cetuximab) remains a cornerstone biologic for the treatment of RAS wild-type metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the head and neck (SCCHN). As a recombinant human/mouse chimeric monoclonal antibody, Erbitux specifically binds to the epidermal growth factor receptor (EGFR), effectively inhibiting tumor cell growth and induction of apoptosis. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the international distribution of Erbitux to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated cold-chain logistics and comprehensive pharmaceutical documentation. Technical Product Profile: Erbitux (Cetuximab) 5mg/mL Erbitux is supplied as a sterile, colorless liquid for intravenous (IV) infusion, requiring precision handling and strict temperature maintenance. Product Specifications Active Ingredient: Cetuximab. Concentration: 5 mg/mL (available in 100 mg/20 mL and 500 mg/100 mL vials). Mechanism of Action: EGFR Antagonist; binds to the extracellular domain of EGFR to block ligand-induced phosphorylation. Therapeutic Class: Monoclonal Antibody (Antineoplastic Agent). Storage Requirements: Must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Primary Clinical Indications Metastatic Colorectal Cancer (mCRC): Indicated for RAS wild-type, EGFR-expressing mCRC as a single agent or in combination with chemotherapy (FOLFIRI/FOLFOX). Head and Neck Cancer (SCCHN): Used in combination with radiation therapy for locally advanced disease or with platinum-based therapy for metastatic cases. Key Features & Global Logistics Excellence Precision Targeting: Erbitux specifically inhibits the overexpressed EGFR pathways found in various solid tumors, minimizing damage to non-EGFR-expressing cells. Synergistic Efficacy: Proven to enhance the effectiveness of standard radiotherapy and cytotoxic chemotherapy regimens. Validated Cold-Chain Shipping: Ernest Oncology utilizes IATA-certified temperature-controlled packaging to ensure the biologic integrity of Erbitux during transit to London, Abu Dhabi, or Sydney. Global Compliance: Every shipment is accompanied by a Certificate of Analysis (CoA) and adheres to international Good Distribution Practices (GDP). Global Export Reach: USA, UK, UAE, Australia, & South Africa Ernest Oncology excels in managing the complex regulatory requirements for exporting targeted biological therapies from India to major global healthcare hubs. USA: Supplying specialized oncology centers and wholesale distributors with high-quality Cetuximab vials. UK & London: Supporting the NHS and private oncology clinics with reliable, cost-effective access to monoclonal antibodies. Abu Dhabi, UAE: Catering to the advanced medical networks of the Middle East with rapid, secure biologic delivery. Australia: Navigating TGA standards to provide Australian oncology departments with essential cancer medications. South Africa: Strengthening the Southern African oncology sector through consistent bulk supply and competitive pricing. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of Erbitux and specialized oncology medications. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Zybev Injection (Bevacizumab): Premium Anti-Angiogenic Biological Therapy – Global Supply by Ernest Oncology In the evolving oncology landscape of 2026, Zybev Injection (active ingredient Bevacizumab) has solidified its position as a critical biosimilar for the management of advanced solid tumors. As a recombinant humanized monoclonal antibody, Zybev provides clinical efficacy equivalent to the reference biologic, targeting the Vascular Endothelial Growth Factor (VEGF) to inhibit tumor-induced angiogenesis and arrest cancer progression. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Zybev to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring meticulous cold-chain management and rapid global delivery. Technical Product Profile: Zybev (Bevacizumab) Zybev is a biological therapy administered via intravenous (IV) infusion, designed to disrupt the blood supply that tumors require to grow and metastasize. Product Specifications Active Ingredient: Bevacizumab (Biosimilar) Available Strengths: 100 mg / 4 mL and 400 mg / 16 mL Single-dose Vials Pharmacological Class: Vascular Endothelial Growth Factor (VEGF) Inhibitor; Monoclonal Antibody Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Primary Clinical Indications Metastatic Colorectal Cancer (mCRC): Used as a foundational treatment in combination with fluoropyrimidine-based chemotherapy. Non-Small Cell Lung Cancer (NSCLC): First-line treatment for unresectable, locally advanced, recurrent, or metastatic non-squamous NSCLC. Glioblastoma: For the treatment of recurrent glioblastoma in adult patients. Metastatic Renal Cell Carcinoma (mRCC): In combination with interferon alfa. Ovarian & Cervical Cancers: Effective in persistent, recurrent, or metastatic cases when combined with specific chemotherapy regimens. Mechanism of Action: The Anti-Angiogenic Approach Zybev works by selectively binding to the VEGF protein, preventing it from interacting with its receptors on the surface of endothelial cells. Angiogenesis Inhibition: By neutralizing VEGF, Zybev prevents the formation of new blood vessels that tumors need for nutrients and oxygen. Vascular Regression: Existing tumor microvasculature undergoes regression, inhibiting tumor growth. Vascular Normalization: It helps normalize the remaining tumor vasculature, reducing interstitial fluid pressure and potentially improving the delivery of co-administered chemotherapy. Global Export Excellence: UK, USA, UAE, Australia, & South Africa Ernest Oncology specializes in navigating the strict regulatory and logistical requirements for shipping temperature-sensitive biosimilars from India to major international hubs. United Kingdom & London: We supply NHS trusts and private oncology clinics in London, adhering to all MHRA biological import protocols. United States: Bulk supply for hospital networks and specialty wholesalers seeking cost-effective, high-quality Bevacizumab biosimilars from India. Abu Dhabi & UAE: Supporting the UAE’s world-class healthcare sector with fast-track, secure, temperature-monitored shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological standards. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology biologics and anti-angiogenic biosimilars. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Pertuzumab Injection: Advanced HER2-Dimerization Inhibitor for Targeted Oncology – Global Supply by Ernest Oncology In the precision medicine landscape of 2026, Pertuzumab Injection remains a cornerstone in the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) positive malignancies. As a recombinant humanized monoclonal antibody, Pertuzumab represents a sophisticated class of targeted therapy—HER2-dimerization inhibitors (HDIs)—designed to disrupt the signaling pathways that drive aggressive tumor proliferation. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Pertuzumab to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, providing end-to-end cold-chain solutions and rigorous documentation for global medical procurement. Technical Product Profile: Pertuzumab Injection Pertuzumab is a biological agent that targets the extracellular domain of the HER2 protein, specifically preventing it from pairing with other members of the HER family. Product Specifications Active Ingredient: Pertuzumab Concentration: 420 mg / 14 mL (30 mg/mL) Single-dose Vial Pharmacological Class: HER2-Dimerization Inhibitor (Monoclonal Antibody) Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Do not freeze. Primary Clinical Indications Metastatic Breast Cancer (MBC): Indicated for use in combination with Trastuzumab and Docetaxel for patients with HER2-positive MBC who have not received prior anti-HER2 therapy. Neoadjuvant Treatment: For patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen. Adjuvant Treatment: For patients with HER2-positive early breast cancer at high risk of recurrence. Mechanism of Action: The Science of Dimerization Blockade Pertuzumab’s therapeutic efficacy lies in its ability to target the HER2 dimerization domain (Domain II). Prevention of Heterodimerization: Pertuzumab inhibits the ligand-induced pairing of HER2 with other HER receptors, most notably HER3. This pairing is the most potent signaling driver for cancer cell survival. Dual Blockade Synergy: When used with Trastuzumab, which binds to Domain IV, the two antibodies provide a comprehensive “Dual Blockade,“ shutting down both ligand-dependent and ligand-independent growth signals. Antibody-Dependent Cellular Cytotoxicity (ADCC): Pertuzumab marks the cancer cells for destruction by the body’s innate immune system, specifically natural killer (NK) cells. Global Export Excellence: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of shipping temperature-sensitive biologicals from India to the world’s most demanding healthcare markets. United Kingdom & London: We supply NHS trusts and private oncology centers in London, adhering to all MHRA biological import protocols and safety standards. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced HER2+ therapy. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological import standards. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Perzumab Injection (Pertuzumab): Targeted HER2-Dimerization Inhibitor – Global Supply by Ernest Oncology In the precision medicine landscape of 2026, Perzumab Injection (containing the active ingredient Pertuzumab) represents a critical breakthrough in the treatment of HER2-positive malignancies. As a humanized monoclonal antibody, Perzumab acts as a HER2-dimerization inhibitor, specifically designed to prevent the pairing of HER2 with other HER receptors, thereby shutting down the aggressive growth signals that drive cancer progression. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Perzumab to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring meticulous cold-chain management and rapid global delivery. Technical Product Profile: Perzumab (Pertuzumab) Perzumab is a biological therapy that targets a different epitope on the HER2 receptor than Trastuzumab, making it an essential component of “dual-blockade“ therapy. Product Specifications Active Ingredient: Pertuzumab Common Strength: 420 mg / 14 mL (30 mg/mL) Single-dose Vial Pharmacological Class: Monoclonal Antibody (HER2-Dimerization Inhibitor) Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Primary Clinical Indications Metastatic Breast Cancer (MBC): Indicated for use in combination with Trastuzumab and Docetaxel for patients with HER2-positive MBC who have not received prior anti-HER2 therapy. Neoadjuvant Treatment: Used as part of a complete treatment regimen for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer. Adjuvant Treatment: For patients with HER2-positive early breast cancer at high risk of recurrence. Mechanism of Action: Dimerization Blockade Perzumab specifically targets the extracellular dimerization domain (Domain II) of the Human Epidermal Growth Factor Receptor 2 (HER2). Inhibition of Pairing: It prevents HER2 from forming pairs (dimers) with other HER family members (HER1, HER3, and HER4), most notably the HER2-HER3 heterodimer. Signaling Interruption: By blocking dimerization, it inhibits the downstream signaling pathways that lead to cell proliferation and survival. Immune System Recruitment: It induces Antibody-Dependent Cellular Cytotoxicity (ADCC), recruiting the body's immune cells to destroy the tumor. Global Export Expertise: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of global pharmaceutical distribution, ensuring that oncology providers have consistent access to high-quality, life-saving biologics. United Kingdom & London: We supply NHS trusts and private oncology centers in London, adhering to all MHRA import guidelines and technical documentation requirements. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced HER2+ therapy. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological standards. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Perjeta Injection (Pertuzumab): Advanced HER2-Dimerization Inhibitor – Global Supply by Ernest Oncology In the precision-driven oncology landscape of 2026, Perjeta Injection (active ingredient Pertuzumab) represents a breakthrough in targeted biological therapy. As a recombinant humanized monoclonal antibody, Perjeta is the first in a class of agents called HER2-dimerization inhibitors (HDIs), specifically designed to work in synergy with Trastuzumab to provide a more comprehensive blockade of HER2 signaling pathways. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Perjeta to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous cold-chain integrity and rapid logistical execution. Technical Product Profile: Perjeta (Pertuzumab) Perjeta targets a different epitope on the HER2 receptor than Trastuzumab, effectively preventing HER2 from pairing (dimerizing) with other HER receptors (HER1, HER3, and HER4). Product Specifications Active Ingredient: Pertuzumab Concentration: 420 mg / 14 mL (30 mg/mL) Single-dose Vial Pharmacological Class: HER2-Dimerization Inhibitor (Monoclonal Antibody) Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Do not freeze or shake. Primary Clinical Indications Metastatic Breast Cancer (MBC): In combination with Trastuzumab and Docetaxel for patients with HER2-positive MBC who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Neoadjuvant Treatment: For patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen. Adjuvant Treatment: For patients with HER2-positive early breast cancer at high risk of recurrence. Mechanism of Action: Dual HER2 Blockade Perjeta’s unique mechanism involves binding to Domain II of the HER2 extracellular domain. Inhibition of Dimerization: Perjeta specifically inhibits the ligand-dependent HER2-HER3 heterodimerization, which is the most potent signaling pair in the HER family. Complementary Action: While Trastuzumab binds to Domain IV to inhibit ligand-independent signaling, Perjeta blocks Domain II. Together, they provide a “dual blockade“ that more effectively shuts down cancer cell growth signals. ADCC Activation: Like other monoclonal antibodies, Perjeta induces Antibody-Dependent Cellular Cytotoxicity (ADCC) to recruit the immune system to destroy tumor cells. Global Export Expertise: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of global pharmaceutical trade, ensuring that oncology providers have consistent access to high-value biological medications. United Kingdom & London: We serve NHS trusts and private oncology centers in London, adhering to all MHRA biological import and safety standards. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced breast cancer care. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with validated, temperature-monitored shipping to Abu Dhabi and Dubai. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological frameworks. South Africa: Strengthening the African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Hertraz Injection (Trastuzumab): Advanced HER2+ Targeted Biological Therapy – Global Supply by Ernest Oncology In the precision-driven oncology landscape of 2026, Hertraz Injection (containing the active ingredient Trastuzumab) stands as a critical biosimilar for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) overexpressing malignancies. Developed to match the clinical efficacy and safety of the reference biologic, Hertraz has expanded access to life-saving monoclonal antibody therapy for patients across the globe. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Hertraz to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, providing end-to-end cold-chain solutions and rigorous documentation for seamless medical procurement. Technical Product Profile: Hertraz (Trastuzumab) Hertraz is a recombinant DNA-derived humanized monoclonal antibody that selectively binds with high affinity to the extracellular domain of the HER2 protein. Product Specifications Active Ingredient: Trastuzumab (Biosimilar) Available Strengths: 150 mg and 440 mg Multi-dose Vials Pharmacological Class: HER2/neu Receptor Antagonist (Monoclonal Antibody) Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Primary Clinical Indications HER2+ Metastatic Breast Cancer: Used as a first-line therapy in combination with taxanes or as a single agent in patients who have received previous chemotherapy. Early Breast Cancer (EBC): Administered following surgery and chemotherapy to significantly reduce the risk of cancer recurrence. Advanced Gastric Cancer: Indicated for HER2+ metastatic adenocarcinoma of the stomach or gastroesophageal junction in combination with cisplatin and a fluoropyrimidine. Mechanism of Action: The Power of Targeted Blockade Hertraz exerts its therapeutic effect by specifically targeting cells that overexpress the HER2 protein, which is responsible for aggressive tumor growth. Receptor Inhibition: Hertraz binds to the HER2 receptors on the surface of cancer cells, blocking the chemical signals that tell the cells to grow and divide. Immune System Recruitment: It marks the cancer cells for destruction by the body’s immune system through Antibody-Dependent Cellular Cytotoxicity (ADCC). Prevention of HER2 Shedding: It prevents the cleavage of the HER2 receptor's extracellular domain, which can otherwise trigger potent oncogenic signaling. Global Export Expertise: UK, USA, UAE, Australia, & South Africa Ernest Oncology specializes in navigating the complex regulatory and logistical requirements for shipping sensitive biologicals from India to the world’s most demanding healthcare markets. United Kingdom & London: We supply NHS Trusts and private oncology centers in London, adhering to all MHRA biological import protocols and batch release standards. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports at competitive price points. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping to major healthcare hubs. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological import standards. South Africa: Strengthening the African healthcare sector with affordable, high-quality cancer drugs from WHO-GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology biologics and targeted biosimilars. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Canmab (Trastuzumab): Premium HER2+ Biosimilar Therapy – Global Supply by Ernest Oncology In the cost-conscious yet quality-driven oncology landscape of 2026, Canmab (active ingredient Trastuzumab) has emerged as a vital biosimilar for the treatment of HER2-positive malignancies. As a recombinant DNA-derived monoclonal antibody, Canmab provides the same clinical efficacy and safety profile as the reference biologic, ensuring that life-saving targeted therapy remains accessible to global healthcare systems. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Canmab to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, providing end-to-end cold-chain solutions and rigorous documentation for seamless customs clearance. Technical Product Profile: Canmab (Trastuzumab) Canmab is a targeted biological therapy designed to interfere with the HER2 receptor, which is overexpressed in certain aggressive cancer types. It is typically supplied as a lyophilized powder for reconstitution and intravenous (IV) infusion. Product Specifications Active Ingredient: Trastuzumab (Biosimilar) Available Strengths: 150 mg and 440 mg Vials Pharmacological Class: Monoclonal Antibody / HER2 Receptor Antagonist Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Primary Clinical Indications HER2+ Metastatic Breast Cancer (MBC): Used both as a monotherapy and in combination with taxanes. Early Breast Cancer (EBC): Administered following surgery, chemotherapy, or radiotherapy to reduce the risk of recurrence. Advanced Gastric Cancer: Specifically for HER2+ metastatic adenocarcinoma of the stomach or gastroesophageal junction. Mechanism of Action: Precision Oncology Canmab functions by targeting the extracellular domain of the Human Epidermal Growth Factor Receptor 2 (HER2). Proliferation Inhibition: By binding to HER2, Canmab inhibits the signaling pathways that promote tumor cell growth. Immune Recruitment: It triggers Antibody-Dependent Cellular Cytotoxicity (ADCC), prompting the patient's immune system to attack and destroy the cancer cells. HER2 Shedding Prevention: It prevents the cleavage of the HER2 receptor, which can otherwise lead to more potent oncogenic signaling. Global Export Excellence: UK, USA, UAE, Australia, & South Africa Ernest Oncology specializes in navigating the strict regulatory and logistical requirements for shipping temperature-sensitive biosimilars from India to major international hubs. United Kingdom & London: We supply NHS trusts and private oncology centers in London, ensuring all MHRA-compliant batch release and import paperwork is provided. United States: Bulk supply for hospital networks and specialty wholesalers looking for cost-effective, high-quality Trastuzumab biosimilars from India. Abu Dhabi & UAE: Supporting the advanced healthcare infrastructure of the Emirates with fast-track, secure, temperature-controlled shipping. Australia: Strategic distribution to regional hospitals and wholesalers, strictly adhering to TGA biological import standards. South Africa: Strengthening the African oncology sector by providing high-quality biosimilars that meet strict regulatory benchmarks. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology biologics and targeted biosimilars. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Herceptin (Trastuzumab): Targeted HER2+ Biological Therapy – Global Supply by Ernest Oncology In the precision medicine landscape of 2026, Herceptin (active ingredient Trastuzumab) remains the definitive standard for treating Human Epidermal Growth Factor Receptor 2 (HER2) positive malignancies. As a recombinant DNA-derived humanized monoclonal antibody, Herceptin has revolutionized the prognosis for patients with HER2+ breast and gastric cancers. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Herceptin to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring meticulous cold-chain management and rapid global delivery. Technical Product Profile: Herceptin (Trastuzumab) Herceptin is a targeted biologic therapy that selectively binds to the extracellular domain of the HER2 protein. It is typically supplied as a lyophilized powder for intravenous (IV) infusion or as a solution for subcutaneous (SC) injection. Product Specifications Active Ingredient: Trastuzumab Common Strengths: 150 mg and 440 mg Multi-dose Vials Pharmacological Class: HER2/neu Receptor Antagonist (Monoclonal Antibody) Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Primary Clinical Indications HER2+ Metastatic Breast Cancer: Used as a first-line treatment in combination with paclitaxel or as a single agent in patients who have received one or more chemotherapy regimens. Early Breast Cancer (EBC): Administered as part of a treatment regimen including chemotherapy, or as a single agent following multi-modality therapy. HER2+ Metastatic Gastric Cancer: In combination with cisplatin and capecitabine (or 5-fluorouracil) for patients who have not received prior anti-cancer therapy for metastatic disease. Mechanism of Action: Targeted HER2 Blockade Herceptin works by specifically targeting cells that overexpress the HER2 protein, which is responsible for aggressive cell growth. Receptor Blockade: Herceptin binds to the HER2 receptors, preventing them from receiving growth signals. Immune System Activation: It marks the cancer cells for destruction by the body’s immune system through Antibody-Dependent Cellular Cytotoxicity (ADCC). Inhibition of Shedding: It prevents the cleavage of the extracellular domain of HER2, which otherwise leads to more aggressive signaling. Angiogenesis Inhibition: It may also limit the blood supply to tumors, further inhibiting growth. Global Supply Chain: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the complex regulatory and logistical requirements for shipping sensitive biologicals from India to the world’s most demanding healthcare markets. United Kingdom & London: We supply NHS Trusts and private Harley Street clinics in London, adhering to all MHRA biological import protocols. United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports at competitive price points. Abu Dhabi & UAE: Supporting the UAE’s world-class oncology centers with fast-track, secure, temperature-monitored shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological standards. South Africa: Strengthening the Southern African oncology sector with high-quality, cost-effective targeted therapies from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology biologics and targeted therapies. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Eposin Injection (Etoposide): Targeted Topoisomerase II Inhibitor for Advanced Oncology – Global Supply by Ernest Oncology In the evolving clinical landscape of 2026, Eposin Injection (containing the active ingredient Etoposide) remains an indispensable antineoplastic agent. As a semi-synthetic derivative of podophyllotoxin, Eposin is a cornerstone in multi-agent chemotherapy regimens designed to treat various solid tumors and hematological malignancies with high precision. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Eposin to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous quality standards and validated cold-chain logistics. Technical Product Information: Eposin Injection Eposin is a cell-cycle-specific cytotoxic agent that acts primarily in the G2 and S phases of cellular division. It is supplied as a sterile, non-aqueous solution for intravenous administration after proper dilution. Product Specifications Active Ingredient: Etoposide USP/BP/IP Common Strengths: 100 mg / 5 mL Vials Pharmacological Class: Antineoplastic (Podophyllotoxin derivative) Storage Requirements: Store at controlled room temperature (15°C to 25°C). Do not freeze. Protect from light. Primary Clinical Indications Small Cell Lung Cancer (SCLC): Typically utilized as a first-line therapy in combination with other chemotherapeutic agents like Cisplatin. Refractory Testicular Tumors: For patients who have already received appropriate surgical and chemotherapeutic treatment. Acute Monocytic and Myelomonocytic Leukemia: Integrated into induction and consolidation protocols. Hodgkin’s & Non-Hodgkin’s Lymphoma: A key component in salvage and high-dose therapy regimens. Choriocarcinoma: Part of multi-drug protocols for gestational trophoblastic tumors. Mechanism of Action: How Eposin Works Eposin exerts its therapeutic effect by inhibiting the enzyme DNA Topoisomerase II, which is essential for DNA replication and transcription. Complex Stabilization: Eposin binds to the DNA-Topoisomerase II complex, preventing the re-ligation of DNA strands. Double-Strand Breaks: This leads to an accumulation of permanent double-strand breaks in the cancer cell's DNA. Mitotic Arrest: The genomic damage triggers the cell's internal checkpoints, arresting the cell cycle in the G2 phase. Apoptosis: The irreparable damage ultimately results in programmed cell death (apoptosis) of the malignant cells. Global Supply Chain: UK, USA, UAE, Australia, & South Africa Ernest Oncology specializes in the logistical complexities of exporting high-quality oncology injectables from India to key international healthcare markets. United Kingdom & London: We serve NHS Trusts and private oncology clinics in London, adhering to all MHRA import standards and safety protocols. United States: Bulk supply for hospital systems and specialty pharmacies seeking verified Indian pharmaceutical exports at competitive rates. Abu Dhabi & UAE: Supporting the UAE’s advanced medical infrastructure with fast-track, secure shipping to major oncology hubs. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA frameworks. South Africa: Strengthening the African healthcare sector with affordable, high-quality cancer drugs from WHO-GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized cancer care products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Toposar Injection (Etoposide): Precision Topoisomerase II Inhibitor – Global Supply by Ernest Oncology In the advanced oncology landscape of 2026, Toposar Injection (containing the active ingredient Etoposide) remains a critical antineoplastic agent. As a semi-synthetic derivative of podophyllotoxin, Toposar is globally recognized for its efficacy in treating refractory cancers, particularly within the lungs and reproductive system. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Toposar to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous quality control and validated medical-grade logistics. Technical Product Information: Toposar Injection Toposar is a cell-cycle-specific cytotoxic agent that acts primarily in the G2 and S phases of cellular division. It is supplied as a sterile, non-aqueous solution for intravenous administration after proper dilution. Product Specifications Active Ingredient: Etoposide USP/BP/IP Concentration: 100 mg / 5 mL and 500 mg / 25 mL Vials Pharmacological Class: Antineoplastic (Podophyllotoxin derivative) Storage Requirements: Store at controlled room temperature (15°C to 25°C). Do not freeze. Protect from light during storage. Primary Clinical Indications Small Cell Lung Cancer (SCLC): Often used as a first-line therapy in combination with Cisplatin or Carboplatin. Refractory Testicular Tumors: For patients who have already undergone surgery and chemotherapy with other agents. Non-Hodgkin’s Lymphoma: Integrated into salvage therapy regimens for aggressive lymphomas. Acute Myeloid Leukemia (AML): Utilized in specific induction and consolidation protocols. Pediatric Oncology: Frequently included in protocols for Wilms’ tumor and neuroblastoma. Mechanism of Action: How Toposar Disrupts Cancer Growth Toposar exerts its therapeutic effect by inhibiting the enzyme DNA Topoisomerase II. DNA Cleavage Stabilization: Toposar binds to the Topoisomerase II-DNA complex, preventing the re-ligation of DNA strands. Double-Strand Breaks: This causes an accumulation of permanent breaks in the DNA structure of the cancer cell. Metabolic Failure: The cell is unable to replicate its genetic material or repair the damage, leading to an arrest in the G2 phase. Apoptosis: The irreparable genomic damage triggers programmed cell death (apoptosis) in rapidly dividing malignant cells. Global Supply Chain: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of global pharmaceutical distribution, ensuring that oncology providers have consistent access to high-quality medications. United Kingdom & London: We supply NHS trusts and private oncology centers in London, adhering to all UK pharmaceutical import and safety standards. United States: Bulk supply for hospital systems and specialty pharmacies seeking verified Indian pharmaceutical exports at competitive price points. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure shipping to the Middle East. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA frameworks. South Africa: Strengthening the African healthcare sector with affordable, high-quality cancer drugs from WHO-GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of oncology injectables and specialized cancer care products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Etopos Injection (Etoposide): Advanced Topoisomerase II Inhibitor for Oncology – Global Supply by Ernest Oncology In the precision-driven clinical landscape of 2026, Etopos Injection (containing the active ingredient Etoposide) remains a cornerstone in the treatment of various hematological and solid malignancies. As a semi-synthetic derivative of podophyllotoxin, Etopos is essential for multi-agent chemotherapy protocols designed to achieve high remission rates in lung cancer, testicular cancer, and lymphomas. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We provide GMP-compliant international distribution of Etopos Injection to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring validated cold-chain integrity and rapid logistical execution. Technical Product Information: Etopos Injection Etopos is a cell-cycle-specific cytotoxic agent that acts primarily in the G2 and S phases of cellular division. It is typically supplied as a sterile non-aqueous solution for slow intravenous infusion after dilution. Product Specifications Active Ingredient: Etoposide USP/BP/IP Common Strengths: 100 mg / 5 mL Vials Pharmacological Class: Antineoplastic (Podophyllotoxin derivative) Storage Requirements: Store at controlled room temperature (15°C to 25°C); protect from light. (Note: Diluted solutions may have specific stability windows). Primary Clinical Indications Small Cell Lung Cancer (SCLC): Used as first-line therapy in combination with other chemotherapeutic agents. Refractory Testicular Tumors: For patients who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic therapy. Acute Monocytic and Myelomonocytic Leukemia: Part of induction and consolidation regimens. Hodgkin’s and Non-Hodgkin’s Lymphoma: Integrated into salvage and high-dose therapy protocols. Ewing's Sarcoma: Utilized in pediatric and adult sarcoma treatments. Mechanism of Action: DNA Topoisomerase II Inhibition Etoposide exerts its cytotoxic effect by stabilizing the “cleavable complex“ between DNA and the enzyme Topoisomerase II. Enzyme Poisoning: Etopos prevents the re-ligation of DNA strands after the enzyme has created a break for untangling. Double-Strand Breaks: This leads to an accumulation of double-strand DNA breaks within the malignant cell. Cell Cycle Arrest: The DNA damage triggers the cell's internal checkpoints, leading to an arrest in the G2 phase. Apoptosis: Irreparable DNA damage ultimately results in programmed cell death (apoptosis). Global Supply & Export Expertise: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of global pharmaceutical trade, ensuring healthcare providers have consistent access to high-quality oncology medications. United Kingdom & London: We serve NHS Trusts and private oncology clinics in London, adhering to all MHRA import guidelines and technical documentation requirements. United States: Bulk supply for hospital systems, clinical research organizations, and specialty pharmacies seeking verified Indian pharmaceutical exports. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure shipping to major healthcare hubs. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA standards. South Africa: Strengthening the Southern African oncology sector with cost-effective, high-quality cancer drugs from GMP facilities. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables and specialized cancer care products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Vinblast Injection (Vinblastine Sulfate): Advanced Antineoplastic Therapy – Global Supply by Ernest Oncology In the precision-driven clinical landscape of 2026, Vinblast Injection (containing the active ingredient Vinblastine Sulfate) remains a cornerstone in the treatment of various hematological and solid malignancies. As a potent vinca alkaloid derived from the Vinca rosea plant, Vinblast is essential for multi-agent chemotherapy protocols designed to achieve high remission rates in both adult and pediatric oncology. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We provide GMP-compliant international distribution of Vinblast Injection to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring validated cold-chain integrity and rapid logistical execution. Technical Product Information: Vinblast Injection Vinblast is a cell-cycle-specific cytotoxic agent that arrests cellular division during the metaphase. It is typically supplied as a sterile, lyophilized plug or a clear solution for intravenous administration. Product Specifications Active Ingredient: Vinblastine Sulfate USP/BP/IP Common Strengths: 10 mg / 10 mL Vials Pharmacological Class: Antineoplastic (Vinca Alkaloid) Storage Requirements: 2°C to 8°C (36°F to 46°F); Strictly requires validated Cold Chain Logistics. Primary Clinical Indications Hodgkin’s Disease: A fundamental part of the ABVD regimen for advanced stages. Non-Hodgkin’s Lymphoma: Utilized in lymphocytic and histiocytic lymphoma protocols. Testicular Cancer: Effective against advanced germ cell tumors. Kaposi’s Sarcoma: Frequently prescribed for HIV-related or classic cases. Letterer-Siwe Disease: Standard treatment for Histiocytosis X. Advanced Breast Cancer: Used when patients are unresponsive to other therapies. Mechanism of Action: Disrupting Malignant Replication Vinblastine sulfate works by interfering with the microtubule dynamics essential for cell division. Tubulin Binding: Vinblast binds to tubulin dimers, preventing their polymerization into microtubules. Mitotic Spindle Inhibition: By preventing spindle formation, the cancer cell cannot separate its chromosomes during the M-phase. Apoptosis: This mitotic arrest triggers programmed cell death (apoptosis) in rapidly dividing malignant cells. Global Supply & Export Expertise: UK, USA, UAE, Australia, & South Africa Ernest Oncology manages the logistical complexities of global pharmaceutical trade, ensuring healthcare providers have consistent access to high-quality oncology medications. United Kingdom & London: We serve NHS Trusts and private oncology clinics in London, adhering to all MHRA import guidelines. United States: Bulk supply for hospital systems and specialty pharmacies seeking verified Indian pharmaceutical exports. Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, temperature-controlled shipping. Australia: Strategic distribution to regional hospitals and wholesalers, maintaining TGA compliance. South Africa: Strengthening the Southern African oncology sector with cost-effective, high-quality cancer drugs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables and specialized cancer care products. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383